Allosteric inhibitors of wild-type PTPN11 that hold the phosphatase in the auto-inhibited confirmation and therefore limit signaling through the RAS/MAPK pathway are currently in clinical trials for cancer (Yuan et al., 2020). The gene discussed is PTPN11; the disease is cancer.